The following article has been retracted due to the investigation of complaints received against it. The Editorial Board found that the first author published the paper without other authors’ consent and approval. Th...The following article has been retracted due to the investigation of complaints received against it. The Editorial Board found that the first author published the paper without other authors’ consent and approval. The scientific community takes a very strong view on this matter, and the OJOG treats such behavior seriously. This paper published in Vol. 3 No. 1, 105-110 (pages), 2013, has been removed from this site.展开更多
To study the effects of 17beta-estradiol （E2 ） and progesterone （P4） levels on superovulatory response and recipients conception rate, the E2 and P4 levels of embryo donor （Borderdale） and recipient ewes （Inner...To study the effects of 17beta-estradiol （E2 ） and progesterone （P4） levels on superovulatory response and recipients conception rate, the E2 and P4 levels of embryo donor （Borderdale） and recipient ewes （Inner Mongolian sheep） were determined during multiple ovulation and em- bryo transfer （MOET）. The results showed that the E2 level increased from the day of initiation by CIDR （Controlled internal drug release devices） treatment and decreased to 3.18± 1.32 pg/ml on the day of superovulatory estrus. On the day of embryo collection, the ewes having higher levels of estrogenic peak showed better superovulatory response than the other groups having comparatively lower levels. On the day of initiation of super- ovulatory treatment, the ewes having lower levels of P4 showed better superovulatory response than those having higher levels of P4. The E2 level of the early abortion group increased from Day 0 to Day 45, while that of two pregnant recipient groups came down from Day 0 to Day 30. The ser- um P4 level of the early abortion group was significantly lower than that of the pregnant recipient groups on Day 45 （ P 〈 0.05）, but no significant difference was found between the two pregnant groups after Day 30. Therefore, the levels of E2 and P, on definite time affect superovulatory re- sponse of donors and conception rate of recipients during MOET.展开更多
Objective: The use of intramuscular 17-alpha-hydroxyprogesterone caproate (17-OHPC) has been shown to be beneficial for the prevention of preterm birth (PTB) in women with a prior history. Not all patients with a prio...Objective: The use of intramuscular 17-alpha-hydroxyprogesterone caproate (17-OHPC) has been shown to be beneficial for the prevention of preterm birth (PTB) in women with a prior history. Not all patients with a prior preterm birth receive 17-OHPC. The purpose of this study was to investigate potential barriers to receiving this therapy. Methods: A retrospective chart review of those patients at our institution who received the diagnosis of “previous preterm delivery” in 2010 and 2011 was performed to see whether they were offered and received 17-OHPC. Patients were considered eligible if they had a prior delivery at less than 36 weeks of gestation secondary to idiopathic preterm labor. For those patients that were deemed eligible but did not receive therapy, an explanation was sought. Results: Sixty-six charts were reviewed in detail. Forty-three patients were considered eligible to receive 17-OHPC. The remaining had medical indications for delivery including premature rupture of membranes (PROM) (15), intrauterine growth restriction (IUGR) (1), and hypertension (2). Of the 43 patients deemed eligible, 17 did not receive 17-OHPC. Of these, eight patients were not offered therapy, 2 patients declined therapy, 3 patients presented with therapy after 28 weeks (too late), and 4 received a prophylactic cerclage as their only therapy. There were no significant differences between the two groups. Conclusion: In an effort to increase 17-OHPC use among eligible patients, we must continually identify physician biases and patient barriers that prevent utilization of this intervention. In addition, patients who deliver preterm should be told the importance of presenting early in subsequent pregnancies in order to receive the full benefits of this therapy.展开更多
The risk of cardiovascular disease increases along with aging. There are increasing interests in researches on the protective effects of hormone replacement therapy (HRT)on cardiovascular system in postmenopausal wome...The risk of cardiovascular disease increases along with aging. There are increasing interests in researches on the protective effects of hormone replacement therapy (HRT)on cardiovascular system in postmenopausal women. In this article we will review how we have explored the evidence of different sex hormones on blood vessels since 1996. The results showed that low-dose HRT significantly protected cardiovascular system in postmenopausal women.However, the high-dose 17β-estradiol (E2), with or without progesterone (P) or testosterone (T), or any hormone alone, as their concentrations increase, may even inhibit the protective effects of low-dose HRT on blood vessels.展开更多
文摘The following article has been retracted due to the investigation of complaints received against it. The Editorial Board found that the first author published the paper without other authors’ consent and approval. The scientific community takes a very strong view on this matter, and the OJOG treats such behavior seriously. This paper published in Vol. 3 No. 1, 105-110 (pages), 2013, has been removed from this site.
基金funded by Agricultural Research Institute"948"Program of China(2000-2005)
文摘To study the effects of 17beta-estradiol （E2 ） and progesterone （P4） levels on superovulatory response and recipients conception rate, the E2 and P4 levels of embryo donor （Borderdale） and recipient ewes （Inner Mongolian sheep） were determined during multiple ovulation and em- bryo transfer （MOET）. The results showed that the E2 level increased from the day of initiation by CIDR （Controlled internal drug release devices） treatment and decreased to 3.18± 1.32 pg/ml on the day of superovulatory estrus. On the day of embryo collection, the ewes having higher levels of estrogenic peak showed better superovulatory response than the other groups having comparatively lower levels. On the day of initiation of super- ovulatory treatment, the ewes having lower levels of P4 showed better superovulatory response than those having higher levels of P4. The E2 level of the early abortion group increased from Day 0 to Day 45, while that of two pregnant recipient groups came down from Day 0 to Day 30. The ser- um P4 level of the early abortion group was significantly lower than that of the pregnant recipient groups on Day 45 （ P 〈 0.05）, but no significant difference was found between the two pregnant groups after Day 30. Therefore, the levels of E2 and P, on definite time affect superovulatory re- sponse of donors and conception rate of recipients during MOET.
文摘Objective: The use of intramuscular 17-alpha-hydroxyprogesterone caproate (17-OHPC) has been shown to be beneficial for the prevention of preterm birth (PTB) in women with a prior history. Not all patients with a prior preterm birth receive 17-OHPC. The purpose of this study was to investigate potential barriers to receiving this therapy. Methods: A retrospective chart review of those patients at our institution who received the diagnosis of “previous preterm delivery” in 2010 and 2011 was performed to see whether they were offered and received 17-OHPC. Patients were considered eligible if they had a prior delivery at less than 36 weeks of gestation secondary to idiopathic preterm labor. For those patients that were deemed eligible but did not receive therapy, an explanation was sought. Results: Sixty-six charts were reviewed in detail. Forty-three patients were considered eligible to receive 17-OHPC. The remaining had medical indications for delivery including premature rupture of membranes (PROM) (15), intrauterine growth restriction (IUGR) (1), and hypertension (2). Of the 43 patients deemed eligible, 17 did not receive 17-OHPC. Of these, eight patients were not offered therapy, 2 patients declined therapy, 3 patients presented with therapy after 28 weeks (too late), and 4 received a prophylactic cerclage as their only therapy. There were no significant differences between the two groups. Conclusion: In an effort to increase 17-OHPC use among eligible patients, we must continually identify physician biases and patient barriers that prevent utilization of this intervention. In addition, patients who deliver preterm should be told the importance of presenting early in subsequent pregnancies in order to receive the full benefits of this therapy.
文摘The risk of cardiovascular disease increases along with aging. There are increasing interests in researches on the protective effects of hormone replacement therapy (HRT)on cardiovascular system in postmenopausal women. In this article we will review how we have explored the evidence of different sex hormones on blood vessels since 1996. The results showed that low-dose HRT significantly protected cardiovascular system in postmenopausal women.However, the high-dose 17β-estradiol (E2), with or without progesterone (P) or testosterone (T), or any hormone alone, as their concentrations increase, may even inhibit the protective effects of low-dose HRT on blood vessels.
